← All trials
NCT06652737
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2025
- Primary completion
- Jul 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Oct 22, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 90
- Arms / groups
- 11 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanaria Inc.Lead sponsor
- Groupe de Recherche Action en Santé (GRAS), Burkina FasoCollaborator
- University of WashingtonCollaborator
- Sanaria Inc.Official
- University of MarylandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.